SequelSEC

Veradermics, Inc MANE

Pharmaceutical Preparations · CIK 0001827635 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$29.55M
Fiscal year ended 2026-06-30
Free cash flow
-$14.51M
Fiscal year ended 2026-06-30

Veradermics, Inc (MANE) reported net income of -$23.50M for the fiscal year ended 2026-06-30. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Veradermics, Inc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Veradermics, Inc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$29.55MUnavailable-$43.36M-$16.07MUnavailableUnavailable
Net income-$23.50MUnavailable-$41.95M-$15.64MUnavailableUnavailable
Research & development$18.61MUnavailable$36.29M$14.33MUnavailableUnavailable
Weighted-average diluted sharesshares 40.44MUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$23.50MUnavailable-$41.95M-$15.64MUnavailableUnavailable
Income tax expense$0Unavailable$0$0UnavailableUnavailable
Diluted EPS$-0.58UnavailableUnavailable$-24.19UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$10.95MUnavailable$7.07M$1.74MUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Veradermics, Inc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Cash & equivalents$319.33MUnavailable$21.77MUnavailableUnavailable$53.08M
Total assets$825.74MUnavailable$152.62MUnavailableUnavailable$55.54M
Current assets$824.75MUnavailable$152.49MUnavailableUnavailable$55.54M
Total liabilities$12.12MUnavailable$9.16MUnavailableUnavailable$4.72M
Current liabilities$11.69MUnavailable$9.15MUnavailableUnavailable$4.72M
Total equity incl. NCI$813.61MUnavailable-$121.01M-$76.07MUnavailable-$48.48M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$5.92MUnavailable$2.13MUnavailableUnavailable$2.25M

Cash flow

Veradermics, Inc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Operating cash flow-$14.49MUnavailable-$42.64M-$15.64MUnavailableUnavailable
Capital expenditures$21.00KUnavailable$5.00K$0UnavailableUnavailable
Investing cash flow-$277.29MUnavailable-$94.78M-$8.33MUnavailableUnavailable
Financing cash flow$442.70MUnavailable$150.59M$129.00KUnavailableUnavailable
Net change in cash$150.92MUnavailable$13.17M-$23.84MUnavailableUnavailable
Stock-based compensation$3.52MUnavailable$1.11M$115.00KUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Veradermics, Inc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Free cash flow-$14.51MUnavailable-$42.65M-$15.64MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio70.53xUnavailable16.66xUnavailableUnavailable11.77x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MANE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-30View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

6 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationreview2025-12-31

Difference 264477000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2024-12-31

Difference 99297000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.